AN IMPLANTABLE CONTAINMENT APPARATUS FOR A THERAPEUTICAL DEVICE AND METHOD FOR LOADING AND RELOADING THE DEVICE THEREIN

Abstract: The invention relates generally to an implantable containment apparatus made of selectively permeable material. In particular, the implantable containment apparatus is used to contain a therapeutical device, such as a drug delivery device, a cell encapsulation device, or a gene therapy device. A therapeutical device can be easily placed and replaced in an apparatus of the present invention without damaging tissues associated with the selectively permeable material of the apparatus.

Description: A TV T A\TABT.F CO\TAT \fF\T APPAR ATT τς FOR A THFRAPFI. TCAT FVTΓF AND METHOD r^ LOADING A\D RELOADING THF DFVICE THEREIN πELD OF THF TNVFNTTn This invention relates generally to an implantable containment apparatus made of selectively permeable material. In particular, the implantable containment apparatus is used to contain a merapeutical device, such as a drug delivery device, a cell encapsulation device, or a gene therapy device. A therapeutical device can be easily placed and replaced in an apparatus of the present invention without damaging tissues associated with the selectively permeable material of the apparatus. BACKGROUND OF THF TNVFNTTON Various implantable therapeutical devices, such as drug delivery, gene therapy, and cell encapsulation devices, have been disclosed over the years. A common feature of most of these devices is the use of selectively permeable, or semi- permeable, membranes to construct all or part of the device. These membranes contain their respective therapeutic agents and delivery systems within the particular device while being permeable to the desired therapeutical product. For cell encapsulation devices, the membranes are also permeable to life sustaining substances and to cellular waste products. When implanted in a recipient, the typical biological response by the recipient to most of these therapeutical devices is the formation of a fibrotic capsule around the device. With most drug delivery and gene therapy devices, this can limit the performance of the device, particularly when the therapeutic agent has a short half- life. For cell encapsulation devices, a fibrotic capsule encasing the device most often deprives the encapsulated cells of life sustaining exchange of nutrients and waste products with tissues of a recipient. The result is usually fatal to the encapsulated cells. Furthermore, a fibrotic capsule encasing a therapeutical device usually makes surgical retrieval of the device difficult. When certain therapeutical devices are implanted in a recipient, predominantly vascular tissues of the recipient can be stimulated to grow into direct, or near direct, contact with the device. On one hand, this is desirable because the therapeutical product of the device can then be delivered directly to the circulation of the recipient through the vascular tissues that are in contact with the device. On the other hand, this is undesirable because once vascular tissues of a recipient have grown in contact with one of these implantable therapeutical devices, removal of the device requires surgical dissection of the tissues to expose and remove the device. Surgical dissection of vascular tissues, particularly capillary tissue, can often be a difficult and painful procedure. Whether encased in a fibrotic capsule or surrounded with vascular tissue, the problem of retrieving these implanted devices is a considerable drawback of the devices. For cell encapsulation devices, an alternative to retrieving and replacing the entire device in a recipient is to retrieve and replace the cells contained in the device. U.S. Patent No. 5,387.237, issued to Fournier et al., is a representative example of a cell encapsulation device that has at least one opening into the device through which cells can be introduced and removed. Cells are introduced and removed in this, and other similar devices, as a suspension or slurry. Since most cell encapsulation devices are intended to correct a metabolite deficiency in a recipient caused by dysfunction or failure of certain of the recipient's cells, tissues, or organs, the source of the replacement cells is rarely the recipient. In a situation where non- autologous cells are used in this type of cell encapsulation device, the problem of contaminating a recipient with the foreign cells during loading, removal, or refilling of the device is ever present. One solution to this contamination problem would be to enclose the cells in a container that can be placed, removed, and replaced in a device as a unit. A retrievable cell encapsulation envelope enclosed in an implantable permselective membrane for use as an artificial endocrine gland is disclosed in U.S. Patent No.4,378,016 issued to Loeb. The Loeb device comprises a housing made of an impermeable hollow stem and a permselective membrane sack. The hollow stem has a distal end defining an extracorporeal segment, a percutaneous segment in the mid-region, and a proximal end defining a subcutaneous segment. The sack is adapted to receive an envelope containing hormone-producing cells and has an access opening that is coupled to the proximal end of the hollow stem. In a preferred embodiment, the cell containing envelope is in the form of a flexible collar. The flexible collar is partially collapsible to allow for easier placement and replacement of the envelope in the sack. Once in place, the flexible collar also provides a snug fit between the envelope and the sack. Placement and replacement of a cell containing envelope in the sack portion is accomplished manually with forceps, or the like. Retrieval of the envelope from the sack can be aided with a guidewire attached to the envelope. In one embodiment of the Loeb device, the sack has openings at bo ends that are implanted percutaneously. In this embodiment, the cell containing envelope may be inserted or removed through either end of the device. The housing of the Loeb device is surgically implanted in a recipient through the abdominal wall so the distal end of the stem protrudes from the recipient, the proximal end of the stem resides subcutaneously with respect to the abdominal wall, and the sack portion is placed in the peritoneal cavity surrounded in peritoneal fluid. According to Loeb, the sack allows hormones, nutrients, oxygen, and waste products to flow in and out of the sack while preventing bacteria from entering the patient. The sack and the envelope are said by Loeb to be permeable to nutrients and hormones, but impermeable to the hormone-producing cells and immune response bodies. Upon implantation of the device in a patient, the cells contained therein are said to take over the function of the corresponding natural gland, sense the amount of hormone needed, and produce the correct amount of the desired hormone. Implanted cell encapsulation devices, particularly those intended as an artificial endocrine gland, usually require a high rate of flux of nutrients and waste products between the encapsulated cells in the device and tissues of the recipient. Having a cell encapsulation device in close, or direct, association with a vascular structure usually provides the highest rate of nutrient and waste product flux for such a device. Loeb does not teach the value of vascularization of the sack portion of the housing, however. Nor is the Loeb device implanted in a part of me body that is particularly vascularized. Brauker et al. disclose a cell encapsulation device in U.S. Patent No. 5,314,471 that requires close association of host vascular structures with the device. According to Brauker et al., "conventional implant assemblies and methodologies usually fail to keep the implanted cells alive long enough to provide the intended therapeutic benefit." Cell death in these implanted devices is said by Brauker et al. to be due in large part to an ischemia imposed on the cells during the first two weeks following implantation. Brauker et al. conclude that "the cells die because conventional implant assemblies and methodologies themselves lack the innate capacity to support the implanted cells' ongoing life processes during the critical ischemic period, when the host's vascular structures are not nearby." Brauker et al. state that in order for implanted cells to survive and function on a long term basis, the host must grow new vascular structures in association with me device. Brauker et al. note that a host will not naturally provide new vascular structures to an implanted cell encapsulation device. According to Brauker et al., the host must be stimulated by the implant assembly itself to grow new vascular structures close to the cell encapsulation device. Angiogenic stimulus can be provided by angiogenic factors applied to the cell boundary of the Brauker et al. device or by certain cell types encapsulated in the device. Growth of vascular tissue in association with a device of Brauker et al. will make removal of the device from a host difficult, however. An implantable containment apparatus made of selectively permeable polymeric material that permits a therapeutical device, such as a drug delivery, a gene therapy, or a cell encapsulation device, to be placed and replaced in a recipient without damaging or disturbing tissues associated with the selectively permeable polymeric material would be useful. Such an apparatus that becomes closely associated with vascular structures without the need to supply angiogenic factors to induce the close vascularization would also be useful. A method of easily placing and replacing a therapeutical device in an implantable containment apparatus of the present invention would be further useful. SUMMA Y OF THE INVENTION The present invention is directed to an implantable containment apparatus for a therapeutical device, such as a drug delivery device, a cell encapsulation device, or a gene therapy device. The apparatus is primarily made of selectively permeable material. The selectively permeable material permits flux, or exchange, of solutes between a therapeutical device contained in the apparatus and tissues of a recipient, while excluding cells from growing beyond a desired point through the material. When an apparatus is implanted in a recipient, various tissues from the recipient grow to associate with the apparatus. These tissues grow next to, or partially through, the exterior surface of the apparatus. It is preferred that vascular tissue is the predominant tissue that grows to associate with an apparatus of the present invention. Once growth of a recipient's tissues in association with an apparatus of the present invention has occurred, a therapeutical device can then be easily placed and replaced in the apparatus without damaging or disturbL g the tissues associated with the selectively permeable material of the apparatus. This is preferably accomplished by providing an implantable containment apparatus for a therapeutical device comprising a selectively permeable microporous polymeric material in the form of a tube wherein the tube comprises an exterior surface, an interior surface that defines a luminal space of substantially uniform diameter, and an access means at one end of the tube through which a therapeutical device is insertable into the luminal space of the mbe wherein, once a therapeutical device is inserted into the luminal space of the tube, the therapeutical device is retained within the tube wherein biochemical and therapeutic substances having a molecular weight up to about 5,000,000 MW diffuse across the thickness of the tube between the contents of the therapeutical device contained therein and tissues of a recipient wherein the therapeutical device is removable from the tube through d e access means of the tube and wherein the tube is refutable with a therapeutical device through the access means of the tube. The apparatus can also have an access means at each end of the tube. In this embodiment, a therapeutical device can be inserted and removed from the luminal space of the tube through either access means in the tube. Furthermore, in this embodiment, a fluid stream can be established through both access means of the tube that can then be used to flush a therapeutical device in and out of the luminal space of the tube. Accordingly, the present invention is also directed to a method in which a therapeutical device, such as a drug delivery device, a gene therapy device, or a cell encapsulation device, is easily inserted into, removed from, and replaced in a containment apparatus of the present invention as a unit with a fluid stream. The method involves repeatedly filling and emptying an implantable containment apparatus tube with a therapeutical device, which comprises: (a) providing an implantable containment apparatus in the form of a tube comprised of a selectively permeable polymeric material having an exterior surface, an interior surface defining a luminal space of substantially uniform diameter, and an access means at each end of the tube that permits access to the luminal space of the tube; (b) opening both access means of the implantable containment apparatus tube to access the luminal space of the tube; (c) providing a means of establishing and maintaining a fluid stream through the luminal space of the implantable containment apparatus tube; (d) connecting the fluid stream means of step (c) to one of the opened access means of the implantable containment apparatus tube; (e) establishing a fluid stream dirough the luminal space of the implantable containment apparatus tube with the fluid stream means of step (c); (f) entraining a therapeutical device in the fluid stream; (g) delivering the entrained therapeutical device into the luminal space of the implantable containment apparatus with the fluid stream; (h) discontinuing the fluid stream; (i) disconnecting the fluid stream means of step (c) from the opened access means; (j) closing both access means of the implantable containment apparatus to contain the therapeutical device within me luminal space of the implantable containment apparatus; (k) providing a means of establishing and mamtaining a fluid stream around the therapeutical device and through the luminal space of the implantable containment apparatus; (I) opening born access means of the implantable containment apparatus; (m) connecting the fluid stream means of step (k) to one of the opened access means of the implantable containment apparatus; (n) establishing a fluid stream around the therapeutical device and through the luminal space of the implantable containment apparatus tube to entrain the therapeutical device in the fluid stream; (o) removing the entrained therapeutical device from the luminal space of the implantable containment apparatus with the fluid stream of step (n); and (p) repeating steps (c) dirough (o) as desired. Other features and advantages of the invention will become apparent upon review of the following specification, drawings, and claims. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 illustrates a cross-section of a microporous polymeric material of the present invention ( 1) wherein the selective permeability of the material excludes cells (2) from migrating or growing into the porous spaces of material while permitting bi¬ directional flux of solutes (3) across the thickness of d e material. Figure 2 illustrates a cross-section of a microporous polymeric material of the present invention (1) wherein me selective permeability of the material varies continuously across the thickness of the material as indicated by the gradually increasing density of the stippling in the figure. Figure 3 illustrates a cross-section of a microporous polymeric material of me present invention (1) wherein the selective permeability of the material varies sharply across me thickness of the material as indicated by me sharply increasing density of the stippling in the figure. Figure 4 illustrates a cross-section of a microporous polymeric material of the present invention (1) wherein the selective permeability of the material is varied sharply across me thickness of me material with an additional layer of microporous polymeric material (2). Figure 5 illustrates a cross-section of a microporous polymeric material of the present invention (1) wherein me selective permeability of the material (2) is varied sharply across the thickness of the material with a hydrogel material (3). Figure 5A illustrates a cross-section of a microporous polymeric material of the present invention (1) wherein the selective permeability of the material (2) is varied sharply across the thickness of the material with an additional layer of microporous polymeric material (3) and a further layer of hydrogel material (4). Figure 6 illustrates a cross-section of a microporous polymeric material of the present invention (1) having a cell permeable zone (2) beginning at the exterior surface (3) of the material and continuing across the thickness of the material to a cell exclusion zone (4) within me material adjacent to and continuous with the interior surface (5) of the material. Figure 7 illustrates a cross-section of a microporous polymeric material of the present invention (1) having a cell permeable zone (2) beginning at the exterior surface (3) of the material and continuing across the thickness of the material to a cell exclusion zone (4) within me material adjacent to and continuous with the interior surface (5) of the material, wherein the cell permeable zone (2) is populated with vascular structures (6). Figure 8 is a cross-sectional illustration of a tubular embodiment of the present invention wherein an adhesive (1) is used to attach an access means (2) to a microporous polymeric material (3). Figure 9 A illustrates a tubular embodiment of the present invention (1) for containing a generally cylindrically shaped merapeutical device (2) using the microporous polymeric material (3) illustrated in Figure 7, having an access means (4) attached to one end of me tube. Figure 9B illustrates the embodiment illustrated in Figure 9 A, but with an access means at each end of the tube. Figure 10 illustrates the embodiment depicted in Figure 9A, but with a cell exclusion zone formed witfi a hydrogel material (3) instead of a layer of a microporous polymeric material. Figure 1 1 illustrates an embodiment of the present invention having a plurality of cylindrically shaped containment apparatuses (1) arranged in a radial array attached to a circular planar material (2) to provide a single surgical accession site for the various tubes. Figure 12 illustrates an embodiment of the present invention having a plurality of cylindrically shaped containment apparatuses (1) arranged in a radial array attached to a planar material (2) mat generally follows the oudine of the array to provide a single surgical accession site for the various tubes. Figure 13 illustrates an embodiment of the present invention having a plurality of cylindrically shaped containment apparatuses ( 1) arranged generally parallel to one another and attached to a planar material (2). Figure 14 illustrates a tubular embodiment of me present invention (1) having access means (2) at both ends of me mbe, wherein the access means are positioned and maintained sufficiently close together with a holding means (3) so that the apparatus is implantable and accessible at a single site in a recipient. Figures 15A and 15B, respectively, illustrate a method of placing and removing a therapeutical device (1) in a tubular apparatus of the present invention (2) with a fluid stream. Figure 15C illustrates a group of assemblies used to place a generally cylindrical therapeutical device in a tubular apparatus of the present invention. The assemblies illustrated in Figure 15C include an apparatus of the present invention (1) having access means (2), holding means (3), and sealing means (4). Figure 15C also includes an illustration of two fluid stream means (5 and 6) and a connector (7), having a cavity with a pin (8) on one side (hereinafter the "pin-side") and a cavity (9) on the other side of me connector (7) without a pin (hereinafter the "non-pin- side"), mat is adapted to mate with the access means (2) of the apparatus (1) to facilitate placement, retrieval, or replacement of a therapeutical device in the apparatus. Figure 16 illustrates a tubular form of the present invention curved into a plurality of convolutions ( 1 ) and held in shape by a planar material (2). Figure 17 illustrates a tubular form of the present invention curved into a generally spiral shape (1) and held in shape by a planar material (2). Figure 18 illustrates a tubular form of the present invention curved into a meandering shape (1) and held in shape by a planar material (2). Figure 19 illustrates a pair of dies (1) having raised tracks (2) elevated above me surface each member of the die pair. It is understood mat the inventions are not limited in use to the details of construction or methodologies there set forth or as illustrated in me drawings. The invention is capable of other embodiments and of being practiced and carried out in various wavs. DETAILED DESCRIPTION OF THE TNVF JTTON The present invention is directed to an implantable apparatus for containment of a therapeutical device, such as a cell encapsulation device, a drug delivery device, or a gene therapy device. Once positioned within the apparatus, the permeable portion of the exterior surface of the therapeutical device and the inner, or luminal, surface of the apparatus are preferably in direct contact. When containing a therapeutical device, an implanted apparatus permits exchange of biochemical substances and merapeutic agents across the thickness of the tube between the contents of the device and tissues of a recipient. An important feature of me present invention is the ability to easily place and replace such a device in an implanted apparatus without damaging tissues of a recipient associated with the apparatus. The apparatus of the present invention is made in a shape that conforms, at least in part, to the form of the therapeutical device the apparatus is intended to contain. With cylindrical merapeutical devices, for example, an apparatus of me present invention is preferably in a tubular form. Other shapes contemplated for the present invention include, but are not limited to, discs, spheres, inflated ovals, cylinders, and/or irregular geometric shapes. The present invention is made, primarily, of a porous polymeric material having selective seiving properties. A selectively seiving porous polymeric material controls passage of solutes, biochemical substances, viruses, and cells, for example, through the material, primarily on the basis of size. In general, as the average pore size of a porous polymeric material increases, increasingly larger biochemicals and biological entities are able to pass through the material. In the present invention selectively seiving porous polymeric materials capable of preventing the passage of biological cells through the material, while permitting biological molecules to pass through the material, are preferred. Porous polymeric materials suitable for construction of an apparatus of the present invention include, but are not limited to, stretched polytetrafluoroemylene, stretched polypropylene, stretched polyethylene, or porous polyvinylidene fluoride, woven or non-woven collections of fibers or yarns, such as "Angel Hair," described by W. French Anderson in Science, vol. 246, pp747-749, or by Thompson et al. in Proc. Natl. Acad. Sci. USA, vol. 86, pp7928-7932 (1989), or fibrous matrices, such as those described by Fournier. et al. in U.S. Patent No. 5.387,237, ei er alone or in combination. Stretched, or expanded, polytetrafluoroethylene is preferred. Stretched polytetrafluoroethylene is characterized as a porous material having void spaces defined by nodes and fibrils. Methods for making stretched polytetrafluoroethylene are taught by Gore in U.S. Patent Nos. 3,953,566 and 4, 187,390, each of which is incorporated herein by reference. For stretched polytetrafluoroemylene, or similar fibrillated material, the pore size is related to the fibril length of me material and me diickness of me material. Pore size may be measured by porometry, such as that provided by me Coulter porometer (Coulter Corp.) Alternatively, fibril length is measured as described in U.S. Patent 4,482,516, issued to Gore, which is incorporated herein by reference. The fibril length of porous stretched polytetrafluoroethylene that has been stretched, or expanded, in a single direction is defined herein as the average often measurements between nodes connected by fibrils in the direction of stretching. Ten measurements are made in the following manner. First, a photomicrograph is made of a representative portion of me sample surface, of adequate magnification to show at least five sequential fibrils within the length of the photomicrograph. Two parallel lines are drawn across the length of the photomicrograph so as to divide the photograph into diree equal areas, with the lines being drawn in the direction of stretching and parallel to the direction of orientation of the fibrils. Measuring from left to right, five measurements of fibril length are made along the top line in the photograph beginning with the first node to intersect the line near the left edge of the photograph and continuing with consecutive nodes intersecting the line. Five more measurements are made along the other line from right to left beginning with the first node to intersect the line on the right hand side of the photograph. The ten measurements obtained by mis method are averaged to obtain the fibril length of the material. For a porous, stretched polytetrafluoroethylene material that has been stretched in more than one direction, the fibril lengm is estimated by examining a representative photomicrograph of the material surface and comparing fibril lengths as described above in a manner that represents the various directional orientations of the fibrils. Thicker fibrillated materials generally have more tortuous pathways connecting one end of a pore to the other end of me pore. As a result, a thicker fibrillated material may have pores mat are larger than me entity sought to be excluded by the pores, but will remain resistant to passage of the entity through the pores due to the increased tortuosity of the pathways of the pores in the thicker material. In the present invention, the fibril length and the thickness of a stretched polytetrafluoroethylene material is chosen to form pores mat resist cellular ingrowth across the thickness of the material beyond a desired point, while being selectively permeable to macromolecules up to a molecular weight of about 5,000,000 MW. For some selectively permeable porous polymeric materials suitable for use in the present invention, the molecular weight cutoff, or sieving property, of the material begins at the surfaces of the material. As a result, certain solutes and/or cells do not enter and pass through the porous spaces of the material from one side to the other. This does not prevent cells from growing next to or on the exterior surface of the material, however. (See Figure 1) In one embodiment, tissues of a recipient, including vascular endothelial cells, grow to contact, but not penetrate, the exterior surface of the present invention. The vascular endomelial cells can combine to form capillaries thereon. Such capillary formation or neovascularization of the present invention permits fluid and solute flux between tissues of a recipient and the contents of a therapeutical device to be enhanced. Otiier selectively permeable porous polymeric materials can be constructed or modified to have a selective permeability that varies across the thickness of the material. The permeability of a porous polymeric material can be varied continuously across the thickness of the material (See Figure 2) or varied sharply from one cross- sectional area of the material to another to form a stratified structure. (See Figure 3) In one embodiment of the present invention, the permeability of a porous polymeric material is varied across its thickness with additional layers of porous polymeric material. (See Figure 4) The additional layers of porous polymeric material may have the same composition and permeability as the initial layer of material or the additional layers may be of a different composition and/or permeability. In another embodiment, the selective permeability of a porous polymeric material for use in the present invention is varied by impregnating the void spaces of the porous polymeric material with a hydrogel material. Hydrogel material can be impregnated in substantially all of the void spaces of a porous polymeric material or in only a portion of me void spaces. For example, by impregnating a porous polymeric material with a hydrogel material in a continuous band within the material adjacent to and/or along the interior surface of a porous polymeric material, the selective permeability of the material is varied sharply from an outer cross-sectional area of the material to an inner cross-sectional area of e material. (See Figure 5) The amount and composition of hydrogel material impregnated in a porous polymeric material depends in large part on the particular porous polymeric material used to construct an apparatus of me present invention, the degree of permeability required for a given application, and the biocompatibility of the hydrogel material. Examples of suitable hydrogel materials for use in the present invention include, but are not limited to, HYP AN® Structural Hydrogel (Hymedix International, Inc., Dayton, NJ), non-fibrogenic alginate, as taught by Dorian in PCT/US 93/05461, which is incorporated herein by reference, agarose, alginic acid, carrageenan, collagen, gelatin, polyvinyl alcohol, poly(2-hydroxyethyl memacrylate, poly(N-vinyl-2-pyrrolidone), or gellan gum, either alone or in combination. HYP AN® Structural Hydrogel is preferred. The total thickness of a stretched polytetrafluoroethylene/hydrogel composite ranges from about 2 microns to about 1000 microns. The permeability of the porous polymeric material can be varied sharply across the thickness of the material with an additional layer of porous polymeric material and a further layer of hydrogel material. (See Figure 5 A) An advantage of this embodiment is the additional protection provided an implant recipient against contamination with cells from a failed cell encapsulation device contained in an apparatus of the present invention. In addition, this configuration will provide a strong cell and humoral immunoisolarion barrier. In one embodiment, the permeability of the porous polymeric material is selected to permit growth of cells from a recipient into, but not through, the material. In this embodiment, a cell permeable zone is formed in the void spaces of a porous polymeric material starting at the exterior surface of the material and continuing to a point within the material adjacent to the interior surface of the apparatus where the permeability of the porous polymeric material to cells is sharply decreased so that cells that have migrated into the void spaces of the material cannot migrate further and penetrate the interior surface of the apparatus (See Figure 6). The region of the porous polymeric material in which cells cannot migrate or grow is referred to as a cell exclusion zone. A cell exclusion zone in an apparatus of the present invention prevents invasive cells from entering the lumen of the apparatus and contacting, adhering to, fouling, ingrowing, overgrowing, or otherwise interfering with a therapeutical device contained wid in the apparams. To exclude invading host cells from growing through to the interior surface of the apparatus, the pore size of the cell exclusion zone should be less man about 5 microns, preferably less man about 1 micron, most preferably less than about 0.5 microns, as measured by porometry, or the permeability suitably adjusted with a hydrogel material. A cell exclusion zone can be formed in a stretched polytetrafluoroethylene material having a cell permeable zone by impregnating the void spaces of the polytetrafluoroethylene material with a hydrogel material in a continuous band within the polytetrafluoroethylene material adjacent to and/or along the interior surface of me stretched polytetrafluoroethylene material of an apparams. (See Figure 10) The preferred hydrogel material is a HYPAN® Structural Hydrogel (Hymedix International Inc., Dayton, N.J.) In particular, HYPAN® Structural Hydrogel catalog numbers HN-68 and/or HN-86 are suitable for use in the present invention. In general, the hydrogel material comprising the cell exclusion zone has a thickness ranging from about 2 microns to about 100 microns, preferably between about 25 microns and about 50 microns. In general, a hydrogel material used to form a cell exclusion zone in a stretched polytetrafluoroemylene material of the present invention is impregnated into the void spaces of the polytetrafluoroethylene materials after the material has been shaped substantially into its final form. A hydrogel material is rarely subjected to the temperatures described below for laminating stretched polytetrafluoroethylene materials together. Various cell types can grow into the cell permeable zone of a porous polymeric material of an apparatus of the present invention. The predominant cell type that grows into a particular porous polymeric material depends primarily on the implantation site, the composition and permeability of the material, and any biological factors, such as cytokines and/or cell adhesion molecules, for example, that may be incorporated in the material or introduced through the apparatus. Suitable biological factors for use in the present invention include, but are not limited to, protein and peptide cytokines, such as vascular endothelial growth factor (VEGF), platelet derived endothelial cell growth factor (PD-ECGF), fibroblast growth factor (FGF), peptides with the amino acid sequence gly-his-lys or tiieir palindromes, with or without salt-bridged copper (II), polysaccharides with angiogenic activity, such as heparin. angiogenesis stimulating lipids, such as oleic acid, or metals, such as copper, either alone or in combination. In the preferred embodimenζ vascular endothelium is me predominant cell type that grows into a porous polymeric material for use in the present invention. Vascularization of the porous polymeric material by a well established population of vascular endothelial cells in the form of a capillary network is encouraged to occur as a result of neovascularization of me material from tissues of a recipient into and across the diickness of the material very close to the interior surface of the apparams, but not across the cell exclusion zone. (See Figure 7) Though vascularization of the present invention can occur without the addition of biological factors, angiogenic factors, such as those mentioned above, can be used to enhance vascularization of the apparams. In addition, angiogenesis can be stimulated by conditions, such as hypoxia. This neovascularization of an apparatus of the present invention improves mass transport of therapeutic drugs or biochemical substances between the interior surface of the apparams and tissues of a recipient, thereby enhancing me quantity and rate of transport of therapeutic drugs or biochemical substances between the contents of a therapeutical device contained in the apparams and tissues of the recipient. In higher animals, nearly all cells are within about 100 microns of a capillary. Therefore, to achieve maximum exchange of materials between a therapeutical device and tissues of a recipient, it is preferred mat the maximum distance ingrown capillaries should be from the lumen of the present invention is less than about 100 microns, more preferably less than about 50 microns, and most preferably less than about 25 microns. Accordingly, the cell exclusion zone in this embodiment of the apparatus should be less than about 100 microns, preferably less than about 50 microns, and most preferably less than about 25 microns, in thickness. In addition to permitting vascularization of the porous polymeric material, the permeability of the porous polymeric material is chosen to selectively permit passage of biochemical substances, including therapeutic drugs, having molecular weights up to about 5,000,000 MW across the thickness of the material. Since a chronic inflammatory response to the present invention has not been observed in experimental animals, it is believed that vascularization of the apparatus proceeds along with the wound healing process of me implantation site. Vascularization and other tissue ingrowth of the cell permeable zone of an apparams of the present invention anchors the apparams in the implantation site. This is an important feature, as migration of conventionally implanted therapeutical devices is often a concern. For a tubular apparams of me present invention, anchorage of the apparams in an implantation site with ingrown host tissues assists in maintaining the shape of me implanted apparams. Maintaining me shape of a. tubular apparams of the present invention is often necessary for easy placement, replacement, and proper functioning of a therapeutical device contained in the apparatus. It is speculated mat vascularization of a porous polymeric material of the present invention could also be accomplished by culturing a population of autologous. or immunogenically neutralized, vascular endothelial cells on the exterior surface of an apparams that would grow and assemble into capillaries connected to the recipient's circulatory system. A vascular subendomelial matrix substrate, such as collagen, fibronectin, laminin, or derivatives ereof, applied to the exterior surface of the porous polymeric material followed by seeding the substrate with cells should allow the cells to grow and differentiate into capillaries thereon. A commercially available subendothelial cell matrix that may be suitable for tiiis purpose in experimental rats is a preparation known under the tradename Matrigel. (Collaborative Laboratories, Inc.) Alternatively, a suitable subendomelial matrix preparation may be obtainable from the vasculature of the implant recipient. An apparams of the present invention has one or more access means through which a therapeutical device is placed, retrieved, and replaced in the apparams. An access means is a closeable opening. The closeable opening is preferably a resealable port, or housing, secured through the porous polymeric material of an apparatus of the present invention or secured in an open end of a tubular, or similarly shaped, apparatus configuration. An access means can have any shape suitable for facilitating placement, retrieval, and replacement of a therapeutical device in the luminal space of a particular apparatus embodiment. Commercially available fittings, such as Luer-lok connectors (Value Plastics, Inc., Fort Collins, CO), can also be used as an access means in the present invention. In one method, an access means is attached to the porous polymeric material of the present invention with a strong, biocompatible adhesive, such as the thermoplastic fluorinated ethylene propylene. (FEP) In a tubular embodiment of the present invention, for example, a preferred access means is a hollow cylindrically shaped fitting made of full density polytetrafluoroethylene (TEFLON®) having a first portion that fits snugly inside an end of the mbe component of the present invention and a second portion mat extends beyond the end of the mbe component to receive and retain a sealing means. The access means is attached to the mbe component by wrapping the first portion of the fitting witii an FEP film to a tfiickness of about 30-40 microns. The FEP film is heat-shrunk in place with hot air. The open end of e tube is stretched slightly as the FEP-wrapped first portion of me access means is inserted into the end of the mbe. Heat is applied to the access means in the area of the FEP between the access means and mbular component to a temperature in excess of that required to melt and shrink the FEP material, about 285 "C, but not high enough to damage the polytetrafluoroethylene material of the tubular component or the access means. Melting the FEP material wrapped around the first portion of the access means causes the FEP to flow into the pores of the stretched polytetrafluoroethylene material and over the surface of the first portion of the access means. Upon cooling, the FEP tenaciously adheres these components together. Optionally, a piece of FEP shrink-wrap film is wrapped around the exterior surface of the tubular component above me underlying first portion of the access means. (See Figure 8) Upon heating and cooling, me FEP will contract. The contracted FEP will function as a compression ring on the mbular component and the access means of the apparatus. Such an FEP compression ring further secures the access means to the end of the mbe. If the FEP shrink-wrap material is heated slightly above its melting point for an extended period of time, i.e. about 20-60 seconds, the material can melt and flow into the pores of the stretched polytetrafluoroethylene material and contact the FEP material wrapped around the first portion of me access means that will have also melted. Once these two melted FEP thermoplastic materials are in contact wim one another, they flow together to form a continuous band of FEP from the outer surface of the first portion of me access means, through the stretched polytetrafluoroethylene material of the tubular component to the outer FEP shrink- wrap coating. The resulting construction has a very strong, air-tight, bond between the access means and the mbular component of the present invention. Alternatively, an access means can be fabricated by injection molding of a fitting onto the end of a stretched polytetrafluoroemylene mbular apparatus using techniques known to those skilled in the art as insert molding. Insert injection molding of an access means on the end of a mbular apparams involves first placing a cylindrical piece of tooling into the luminal space of the mbe followed by placement of the tube end and the cylindrical tool mto a mold cavity. 1 he mold cavity is then filled with a polymeric substance comprised of a thermosetting resin such as polyduTiemylsiloxane, for example, or with a molten thermoplastic such as fluorinated ethylene propylene (FEP), polycarbonate, polyester, or polysulfone, ei er alone or in combination, for example. Following curing of the polymeric resin through appropriate reaction conditions or dirough cooling as required, the mold cavity is opened and the cylindrical mold insert removed from the lumen of the mbe. This is a preferred method due to the smooth transition between the luminal surfaces of the connector and the mbe. An access means can also be a hole in the porous polymeric material with one or more flexible pieces, or flaps, of porous polymeric material positioned to cover and close the hole. The flaps may be formed as part of the apparams or may be attached to the apparams subsequent to its initial construction. An access means comprising a resealable port can be repeatedly opened and closed with a sealing means. Sealing means include, but are not limited to, caps, plugs, clamps, compression rings, or valves, for example. The sealing means may be attached to the access means with friction, by clamping, or with screw means comprised of threads and grooves, for example. Depending on the intended use of the apparams, the access means is sealed with a sealing means to create a hermetical seal, a fluid-tight seal, or a non-fluid-tight seal. An apparatus intended for permanent or long term (i.e. at least about three weeks) implantation in a recipient, is preferably sealed with a hermetical or a fluid-tight seal. Suitable materials for constructing the access and sealing means include, but are not limited to, metallic, ceramic, glassy, elastomeric, or other polymeric materials, ei er alone or in combination. Examples of metallic materials include, but are not limited to, tantalum, cobalt-chrome alloys, titanium and its alloys, stainless steel, or gold, eimer alone or in combination. Examples of ceramic materials include, but are not limited to, aluminas, silicas, zirconias, calcium sulfates, calcium carbonates, calcium phosphates (including hydroxyapatite and beta -tricalcium phosphate), borosilicate glasses, elemental carbon, ALCAP (a ceramic comprising aluminum, calcium, and phosphorous oxides), and bioglasses, either alone or in combination. Examples of elastomeric materials include, but are not limited to silicone, polyurethanes, fluoropolymer rubbers (e.g. Viton), poly(ethylene-co-propylene), and polybutadiene and its copolymers (e.g. Buna-N), eimer alone or in combination. Examples of polymeric materials include, but are not limited to polytetrafluoroemylene, polyethylene, polypropylene, polystyrene, poly(tetrafluoroethylene-co- perfluoropropylene), polyesters, such as, poly(e ylene terephthalate), polycarbonates, poly(methyl methyacrylate), and polyamides, eimer alone or in combination. The primary structural requirement of these materials in an access or sealing means is that they have die strengtii, biocompatibility, and longevity to function permanently or for a long term (i.e. at least about three weeks) in a recipient. Many of the materials used to construct an apparatus of the present invention are inherently radio-opaque. Those materials that are not inherently radio-opaque can be modified to be radio-opaque by impregnation of the material with barium, for example. Other suitable methods for rendering a material radio-opaque are known to those skilled in die art. The radio-opacity of materials used to construct an apparatus of die present invention is mainly used to facilitate surgical placement of the apparams or to locate the apparams in a recipient following implantation. In a preferred embodiment, an apparams of me present invention is in the form of an implantable mbe for containing a generally cylindrically shaped therapeutical device. The implantable tube is made of a stretched polytetrafluoroethylene material having a cell permeable zone extending from die exterior surface of the tube dirough to a cell exclusion zone widiin the material adjacent to and continuous wim die luminal surface of die tube. (See Figure 9A) The cell permeable zone is sufficiently porous for capillaries to form therein. In some tubular embodiments of die present invention, open ends of die tube can be prevented from collapsing with a stent, or core. The stent can be in any shape and made of any biocompatible material suitable for keeping all or part of tubular apparatus in an opened, or expanded, tubular form during storage and or following implantation. Suitable materials for a stent include, but are not limited to, stainless steel, titanium, and hydrogels. To maintain die entire length of a mbular apparatus in an expanded configuration, an inert core simulating the shape and resilience of a tiierapeutical device is placed in die apparatus. The preferred material for such an inert core is HYPAN® Structural Hydrogel. (Hymedix International, Inc., Dayton, NJ) Preferably, die material for the tube is a laminate of at least two layers of a stretched polytetrafluoroediylene material each having different porosities. In this embodiment, die portion of the laminate containing the cell exclusion zone is a layer of stretched polytetrafluoroeύiylene material mat is a very diin, very strong non- woven web composed substantially of fibrils in which mere are essentially no nodes. This layer has an average pore size ranging between about 0.05 and about 0.4 microns, as measured by porometry. The preferred pore size of tfus material for use in the present invention is about 0.4 microns in its laminated, or finished, form. The . duckness of die material in its finished form is between about 1 micron and about 25.4 microns. The preferred method of making this layer of the laminate utilizes a portion of a mediod taught by Bacino in U.S. Patent Application Serial No. 08/403,232 and corresponding PCT Application Serial No. PCT/US95/ , filed June 2, 1995, entitled "Porous PTFE Film And A Manufacturing Method Therefor," which is incorporated herein by reference. In die Bacino me od, after die appropriate polytetrafluoroethylene starting materials are chosen and prepared as a coagulated dispersion of fine powder polytetrafluoroediylene, die coagulated dispersion powders are lubricated with a hydrocarbon extrusion aid, preferably as odorless mineral spirit such as Isopar K (made by Exxon. Corp.). The lubricated powder is compressed into cylinders and extruded in a ram extruder to form tapes. Two or more layers of tape can be stacked togedier and compressed between two rolls. The tape or tapes are compressed between rolls to an appropriate diickness, e.g. 5 to 40 mils, or so. The wet tape is stretched transversely to 1.5 to 5 times its original widdi. The extrusion aid is driven off widi heat. The dried tape is dien expanded, or stretched, longitudinally between banks of rolls in a space heated to a temperature that is below the polymer melting point of 327'C. The longitudinal expansion is such mat the ratio of speed of die second bank of rolls to die first bank is 10-100 to 1, preferably 35 to 1. The longitudinal expansion is repeated at a 1-1.5 to 1 ratio. Next, me tape, after the longitudinal expansion, is expanded transversely at a temperature tiiat is less man 327 * C to at least 1.5 times and preferably to 6 to 15 times die input width of die original extrudate while restraining me membrane from longitudinal contraction. While still under constraint die membrane is preferably heated to above me polymer melting point of 327 * C and men cooled. The portion of the laminate containing die cell permeable zone is a stretched polytetrafluoroediylene material made in accordance widi me teachings of U.S. Patent Nos. 3,953,566 and 4,187,390, both issued to Gore, each of which is incorporated herein by reference. The material has an average pore size greater man about 3.0 microns, preferably greater than about 5.0 microns, as measured by fibril lengdi. The tiiickness cf the material ranges from about 10 microns to about 1000 microns, preferably about 40-60 microns. Lamination of these two different stretched polytetrafluoroediylene materials is performed by repeating some of the steps of die above-referenced Bacino method. To perform d e lamination, both above-described stretched polytetrafluoroemylene materials are held togedier and expanded longitudinally between banks of rolls in a space heated to a temperature that is below the polymer melting point of 327 * C. The longimdinal expansion is such diat the ratio of speed of die second bank of rolls to die first bank is 10-100 to 1, preferably 35 to 1, for the material produced by die Bacino method. The longitudinal expansion is repeated at a 1-1.5 to 1 ratio, between the second and diird set of rolls where die material of the '566 patent is joined wid die material from the Bacino method. Next, d e laminate, after the longitudinal expansion, is expanded transversely at a temperature that is less dian 327 * C to at least 1.5 times and preferably to 6 to 15 times the input widtii of die original laminates while restraining the laminate from longimdinal and transverse contraction. While still under constraint the laminate is preferably heated to above the polymer melting point of 327 * C and dien cooled. A preferred method of making a mbular form of the present invention from this laminate is by attaching portions of two or more planar sheets of the laminate together with heat and pressure. Heat and pressure are preferably applied to layers of the laminate with a metal die having elevated tracks raised above d e surface of die die in a pattern d at defines, or reflects, die perimeter of most, or all, of the mbular form. (See Figure 19, for example) The raised tracks concentrate die heat and pressure used to attach the laminates togedier. A thermally and chemically stable core is usually placed between d e layers of laminate in the die within die pattern defining d e perimeter of the tubular form of the apparatus to aid in forming d e tubular form of the construction. Dies can be made diat produce tubes in essentially any shape mat permits easy placement and replacement of a erapeutical device in the invention. It is understood diat this memod is not confined to making mbular forms, but is applicable to other geometric and/or irregular shapes. To make a mbular form with two planar sheets of laminate, me sheets of laminate are first placed togedier widi dieir respective cell exclusion zones facing each other. The laminates are men placed in a die having die desired pattern of raised tracks. A thermally and chemically stable core is placed between die layers of laminate wid in me perimeter of die mbular form outlined by me elevated tracks in the die. Once in die die, die laminates and the core are heated to between about 310'C and about 380°C for about 1-10 minutes at a pressure sufficient to densify the stretched polytetrafluoroediylene material and attach d e planar sheets of laminate together where d e heated tracks contact the sheets of laminate. The tube, core, and attached planar material are allowed to cool to room temperature and dien removed from the die. The core is released from the interior of die mbular form by injecting water between d e core and wall of die tube with a hypodermic syringe, for example. The planar material attached to d e apparatus after its construction can be left attached, trimmed, or removed. Planar material left attached to the apparatus helps to hold the apparams in the proper shape. The planar material also provides a surgeon wid a means of handling the apparams and a means of attaching an apparams securely to an implantation site in a recipient. (See Figure 18, for example) Another way to form an apparams of the present invention in a tubular shape is by wrapping a material made in accordance widi die teachings of Bacino, supra, on a mandrel followed by anod er wrap of a material made in accordance widi d e teachings of Gore, supra. Longitudinal and helical orientations of die wrapped film may be used. This construction is d en heated from about 320 * C to about 380 * C for about 5-10 minutes to bond the respective materials to diemselves and to each other. The overlap of one layer of material with the next layer can range from less than about 10% to about 50%. In many applications, die overlap is preferably about 10%. It is understood mat wraps and laminates of these materials can have no overlap between layers, however. In such an embodiment, me edge of each successive wrap of material abuts die edge of the previous wrap of material. In one embodiment, the tube has an access means at one end of die tube dirough which a dierapeutical device is moved in and out of the luminal space of the tube. In anodier embodiment, die tube has access means at bom ends of die tube dirough either of which a therapeutical device is moved in and out of d e luminal space of die tube. (See Figure 9B) In bodi embodiments, die access means can be repeatedly sealed, opened, and resealed. In one aspect of diis embodiment d e apparams is in die form of one or more substantially straight tubes having access means at one or both ends of each tube. A plurality of tiiese tubes can be arranged in a configuration d at permits multiple dierapeutical devices to be placed in a recipient. (See Figures 11-13) The dierapeutical devices can have die same or different contents. For therapeutical devices having d e same contents, the number of dierapeutical devices contained in diis aspect of die present invention can be varied to more accurately control the dose of the dierapeutic substance delivered to die recipient by die device. Therapeutical devices having different contents can be placed in an apparams of die present invention, tiiereby permitting more than one therapeutical substance to be administered to a recipient simultaneously or sequentially. If a dierapeutical device contained in an apparams of die present invention fails, or otiierwise needs replacement, only the therapeutical device that needs to be replaced is replaced. In anodier aspect of this embodiment, a mbe having access means on both ends of die tube is permanently held in die shape of at least one loop wim a piece of planar material either attached to, or integral with, die porous polymeric material of the tube. In this aspect, die access means are positioned and maintained sufficiently close to one anodier widi a holding means so that the apparams is implantable and accessible for filling and refilling wid a dierapeutical device at a single site in a recipient. (See Figure 14) In order to easily place and replace a dierapeutical device in a mbular apparams of the present invention, a slippery, or lubricous, surface should be present on both die exterior surface of the dierapeutical device and die inner surface of die present invention. The stretched polytetrafluoroediylene material used to construct the present invention is lubricous. Stretched polytetrafluoroediylene in combination with a hydrogel used to form the cell exclusion zone in die apparams makes die luminal surface of die mbe even more slippery. The selectively permeable polymeric materials of most therapeutical devices are also lubricous. Such a membrane impregnated widi a hydrogel material or coated widi a surfactant is more lubricous. Togedier, d e inner surface of a tubular apparatus of d e present invention and a lubricous exterior surface of a dierapeutical device are very lubricous widi respect to each od er. This permits a dierapeutical device to be easily placed and replaced in a mbular apparatus of die present invention. A dierapeutical device can be manipulated in and out of an apparatus of the present invention with forceps and the like. For an apparatus of die present invention having access means at botii ends of die mbe, a therapeutical device is optionally inserted into and removed from die luminal space of a tubular apparatus of die present invention widi a fluid stream. In addition to d e importance of having lubricous surfaces between die interior surface of a tubular apparams of the present invention and die external surface of a therapeutical device during insertion and retrieval of the device from the apparams, when doing so widi a fluid stream it is also important to have sufficient clearance between tiiese components to accommodate die fluid stream and die dierapeutical device entrained dierein during loading, retrieval, and replacement of the device. To this end, die selectively permeable porous polymeric material of the tubular portion of die apparams is radially distensible. Suitable radially distensible materials can stretch slightly under pressure and return to tiieir original dimensions when die pressure is released. Very close or direct contact between die interior surface of an apparams of the present invention and the external surface of a dierapeutical device along substantially d e entire length of die dierapeutical device can be achieved widi tiiis type of material. Alternatively, die inner diameter of the tubular portion of d e apparams can be made larger than the outer diameter of die dierapeutical device die apparams is intended to contain. When tiiis construction is implanted, vascularized, if desired, and loaded widi a dierapeutical device, all, or most, areas of die tubular portion of die apparams collapses against the dierapeutical device contained dierein. This results in direct contact between the interior surface of d e apparams and d e external surface of die dierapeutical device along substantially die entire lengtii of d e dierapeutical device. Even if direct contact is not achieved, die desired result can be obtained if die space that remains between die external surface of die dierapeutical device and the interior surface of the mbular portion of the apparatus is occupied by a material, or stagnate fluid layer, of sufficient diffusive permeability to solutes and products to maintain die necessary rate of mass transport across die wall of die mbe. Suitable materials for tiiis purpose include, but are not limited to, alginate, agar, a hydrogel, such as diose TN grades of hydrogel from Hymedix International, Inc., Dayton, NJ, or a tiiermoreversible gel, such as diose taught by Chick et al. in U.S. Patent No. 5,116,494, which is incorporated herein by reference. The apparatus is collapsed against die dierapeutical device primarily by die wound healing tissues of die implantation site. Suitable porous polymeric materials for eidier of tiiese embodiments include diose listed above, as well as, similar materials having elastomeric components incorporated dierein. A therapeutical device is placed in a mbular apparatus of the present invention wid a fluid stream by first opening botii access means of the mbe. A means of establishing a pressurized fluid stream dirough die luminal spice of the apparams is attached to one of die access means of d e mbe. A means of receiving the fluid stream is attached to d e otiier access means of die mbe. A fluid stream is established in the luminal space of die apparams by causing fluid flow into d e appropriate access means and concurrently out of die otiier access means. This can be accomplished by pumping fluid at positive pressure into one of die access means. To place a therapeutical device in the apparams, a dierapeutical device is first entrained in a pressurized fluid stream and dien inserted into die mbe widi die fluid stream. Once the dierapeutical device is placed in die mbe, the fluid stream is discontinued. When die fluid stream is discontinued, die exterior surface of die dierapeutical device contained in die mbe and the interior surface of die tube are preferably in direct contact. The access means are then closed and die assembly put to use. (See Figure 15 A) Removal of a therapeutical device from a tubular apparatus of the present invention is accomplished by opening botii access means on die mbe and attaching a means of providing a pressurized fluid stream to one of die access means. A pressurized fluid stream is men established around die dierapeutical device and dirough d e luminal space of the mbe to entrain the device in die fluid stream. Once entrained in die fluid stream in die tube, the dierapeutical device is removed from the tube through one of die access means wid d e fluid stream. The fluid stream can eimer push or pull the therapeutical device out of die apparams. (See Figure 15B) If desired, anodier dierapeutical device can be placed in d e apparams by repeating die appropriate insertion steps outlined above. In addition to ease of insertion and retrieval of a dierapeutical device contained in an apparams of die present invention, die present invention has d e advantage of preserving tissues associated widi d e selectively permeable material of die apparatus from damage during placement and exchange of a dierapeutical device in die apparatus. Care should be taken to avoid collapsing die mbe during insertion or removal of a therapeutical device. Maintaining internal positive pressure in a range of about 5-100 psi (i.e. about 3.45 X 10* N/m2 to about 6.89 X 105 N/m2) is usually adequate to prevent collapse of die tube during loading, unloading, and refilling of die mbe with a dierapeutical device. The tiiickness and nominal diameter of a porous polymeric membrane will depend in large part on how much internal pressure a particular containment apparams of die present invention will tolerate. When a dierapeutical device is contained in an apparatus of the present invention, die minimum permissible clearance between die exterior surface of die dierapeutical device and the interior surface of die apparams depends in large part on die particular dierapeutical device embodiment and die tiierapy sought to be achieved widi d e device. For example, cell encapsulation devices implanted in a recipient have a bi-directional flux of solutes between cells in the cell encapsulation device and tissues of die recipient. To maintain a rate of flux sufficient to sustain die viability of die encapsulated cells and to effect die desired dierapeutical result, cell encapsulation devices contained in an apparams of he present invention usually require very small clearances in a range of about 0.5-50 microns or direct contact between die permeable surface of the device and die interior surface of die containment apparams. Drug delivery and gene tiierapy devices may not have die same flux rate requirements as a cell encapsulation device for transport of die particular dierapeutical substance from the device to tissues of a recipient. Accordingly, drug delivery and gene tiierapy devices for use widi die present invention may not need d e minimal clearances required by cell encapsulation devices. Cell encapsulation devices suitable for use in conjunction wid d e present invention preferably are devices of the type disclosed in die patent application of Butler et al., PCT/US94/07190, entitled "Cell Encapsulation Device," which is incorporated herein by reference. Butier et al. disclose a cell encapsulation device d at is generally cylindrical in geometry widi a flexible cell displacing core enclosed in a selectively permeable membrane. The selective permeability of me membrane can be adjusted by impregnating die membrane with an appropriate hydrogel material. The cell displacing core positions d e encapsulated cells in direct, or near direct, contact with the selectively permeable membrane. The encapsulated cells are positioned in d e device at a distance from a nutrient source and at a cell density diat minimizes die diffusion distance biochemical substances must traverse between each encapsulated cell and d e external environment of the device. This configuration enables a maximum number of encapsulated cells to be maintained in a given volume at high levels of viability and productivity. The selectively permeable membrane contains cells within the device while permitting exchange of biochemical substances between the encapsulated cells and die exterior surface of die device. In a situation where die cell encapsulation device is embedded in a recipient and contams allogeneic or xenogeneic cells, die selectively permeable membrane also serves to isolate die encapsulated cells from die immune system of die recipient. Cell encapsulation devices of die type disclosed by Butler et al are suitable for use as implantable therapeutic product delivery systems, implantable artificial organs, or bioreactors. A containment apparams of die present invention, m conjunction witii cells in a cell encapsulation device of die type disclosed by Buder et al , can also function as an implantable dierapeutic product delivery system, an implantable artificial organ, or a bioreactor. A preferred use of die present invention, in conjunction widi a cell encapsulanon device of the type disclose by Butler et al., is as an artificial pancreas. In any one of tiiese utilities, the containment apparams of die present invention enables a complete cell encapsulation device and its entire cache of cells to be easily inserted, retrieved, and replaced in the apparatus as a unit Cell encapsulation devices of die type disclosed by Buder et al., supra, are often several decimeters m lengtii. In order to confme die space occupied by such lengthy cell encapsulation devices to a useful size for surgical implantation, a tubular form of a containment apparatus of the present invention is curved into a plurality of convolutions and permanently held in shape by a planar material. (See Figure 16) Alternatively, die apparatus can be wound into a spiral shape and attached to a planar mateπal (See Figure 17) Any geometry mat serves to confme the space occupied by d e apparams while permitting a cell encapsulation device to be easily placed and replaced in d e apparams is suitable for use in d e present invention, however (See Figure 18, for example) By maintaining the containment apparatus in a gently convoluted conformation, twisting, kinking, or odier extreme bending of a dierapeutical device contamed dierein is minimized or eliminated. Such distortion of a dierapeutical device contamed m an apparams of d e present invention can damage d e device and/or make removal of die device from an apparams difficult or impossible. The planar material can be attached to die apparatus subsequent to its construction or as part of die initial construction of die apparatus, as described above The planar material also serves as a means for handling an apparatus of d e present invention during surgical implantation. In addition, die planar material is a means through which the apparatus is surgically anchored to tissues of a recipient so d e implanted apparams maintains its curved shape and does not move from die implantation site Preferably, the planar mateπal is made of a flexible porous polymeric mateπal Most preferably, die planar mateπal is die same porous polymeπc mateπal used to construct die mbular portion of die apparams and is continuous tiierewidi A drug delivery device suitable for use m conjunction wiϋi die present invention mcludes, but is not limited to, NORPLANT® contraceptive subdermal implant (The Population Councd, Inc , New York, NY) An apparams of the present invention suitable for use with the NORPLANT® contraceptive subdermal implant device can have one or more access means. The NORPLANT® contraceptive subdermal implant device can be mserted, removed, and replaced in an apparams of the present invennon widi a fluid stream, by using surgical forceps, or manually. Gene therapy devices are much like drug delivery devices in at tiiey impart a dierapeutic agent to a recipient unidirectionally from the mteπor of die device to tissues of die recipient. Any of die above-descπbed geometries, or combmations thereof, may be used for an apparatus of the present invention in conjunction with a gene tiierapy device. It is understood, however, mat customized shapes may be needed to perform gene tiierapy in particular parts of a recipient's anatomy. Manipulation of a gene therapy device in and out of an apparatus of the present invention can be accomplished widi a fluid stream, a catiieter system, or surgical forceps, for example. Without intending to limit the scope of die present invention, die following examples illustrate how the present mvention can be made and used. EXAMP ES Example 1 With die following mediod, an apparatus of die present invention may be made in essentially any shape diat permits easy placement and replacement of a dierapeutical device in the apparatus. This example describes d e construction of a tubular form of die apparatus wherein the tube generally follows die patii illustrated in Figure 9A The mbular portion of die apparatus has a planar material attached to die mbe to hold the tube m its patii and to provide anchorage sites for attaching die apparams to the implantation site. Construction of this embodiment is descnbed as follows. The starting material for die apparams is a laminate of two layers of stretched polytetrafluoroediylene materials each having different porosities. In this embodiment, the portion of die laminate containing die cell exclusion zone is a layer of stretched polytetrafluoroediylene material mat is a very tiiin, very strong non- woven web composed substantially of fibrils in which tiiere were essentially no nodes. This layer has an average pore size of about 0.4 microns, as measured by porometry, and a tiiickness of about 1 micron in its laminated, or finished, form. The method of making tiiis layer of die laminate utilized a portion of a metiiod taught by Bacino in U.S. Patent Application Serial No. 08/403,232 and corresponding PCT Application Serial No. PCT/US95/ , filed June 2, 1995, entided "Porous PTFE Film And A Manufacturing Mediod Therefor," which is incorporated herein by reference. After the appropriate polytetrafluoroediylene starting materials were chosen and prepared as a coagulated dispersion of fine powder polytetrafluoroediylene in accordance with die teachings of Bacino, die coagulated dispersion powders were lubricated widi die hydrocarbon extrusion aid Isopar K (made by Exxon. Corp.). The lubricated powder was compressed into cylinders and extruded in a ram extruder to form tapes. Three layers of tape were stacked togedier and compressed between two rolls. The tapes were compressed between rolls to an appropriate thickness of about 15 mils. (375 microns) The wet tape was stretched transversely to about 3.5 times its original widtii. The extrusion aid was driven off widi heat. (i.e. about 260 * C) The dried tape was dien expanded, or stretched, longitudinally between banks of rolls in a space heated to a temperature that was less dian 327'C, i.e. about 305 * C. The longimdinal expansion was such that the ratio of speed of die second bank of rolls to die first bank was 33 to 1. The longimdinal expansion was repeated at a 1.5 to 1 ratio. Next, die tape, after the longitudinal expansion, was expanded transversely at a temperature diat was less than 327 * C, i.e. about 305 * C, at eleven (11) times die input widtii of die original extrudate while restraining d e membrane from longitudinal contraction. While still under constraint d e membrane was heated to above d e polymer melting point of 327 * C, i.e. about 365'C and then cooled to room temperature. The portion of the laminate containing the cell permeable zone was a stretched polytetrafluoroediylene material made in accordance widi die teachings of U.S. Patent Nos. 3,953,566 and 4,187,390, both issued to Gore, each of which is incorporated herein by reference. The material has an average pore size greater than about 5.0 microns, as measured by fibril length, and a tiiickness of about 30 microns. Lamination of tiiese two different stretched polytetrafluoroediylene materials was performed by repeating some of die steps of die above-referenced Bacino method. To perform the lamination, both above-described stretched polytetrafluoroethylene materials were held together and expanded longitudinally between banks of rolls in a space heated to a temperature that was below the polymer melting point of 327 * C, i.e. about 305'C. The longitudinal expansion was such diat d e ratio of speed of the second bank of rolls to die first bank was 33 to 1 for the material produced by the Bacino method. The longitudinal expansion was repeated at a 1.5 to 1 ratio, between die second and third set of rolls where die material of the '566 patent was joined widi die material from die Bacino metiiod. Next, the laminate, after die longimdinal expansion, was expanded transversely at a temperature that was less than 327'C, i.e. about 305'C, to 11 times the input width of the original laminates while restraining die laminate from longimdinal and transverse contraction. While still under constraint die laminate was heated to above die polymer melting point of 327'C, i.e. about 365"C, and then cooled to room temperature. A tubular form of the present invention using this laminate was made by attaching two planar sheets of die laminate togedier along a line diat defines the perimeter of die tubular form. The sheets of laminate were attached widi heat and pressure using a pair of stainless steel machined dies having opposing raised tracks on each member of die die pair. The elevated tracks generally reflect the pattern depicted in Figure 9A. To make the tubular form, two sheets of laminate were first held togedier in die die widi their respective cell exclusion zones facing each other. A tubular core made of full density polytetrafluoroediylene was placed between die layers of laminate witiiin d e outline of d e perimeter defined by die elevated tracks prior to die hearing and pressing process. Once in die die, die laminates were placed in a pneumatic press with platens pre-heated to about 320 * C for about 10 minutes at a pressure sufficient to densify die stretched polytetrafluoroethylene material. When brought together under heat and pressure, the elevated opposing tracks of die dies joined die layers in the areas contacted by die raised tracks. The mbe, core, and attached planar material were allowed to cool to room temperature and dien removed from the die. The core was removed from the interior of die mbular portion of die apparams by injecting water between the core and die wall of the mbe with a hypodermic syringe. The joined portions of die construction formed die perimeter of die mbe except for one end that remained open in order to receive a dierapeutical device. The mbe tiius formed was about 5.08 cm long and an inner diameter of about 0.16 cm, with one closed and one open end. The planar material that remained attached to the apparams after its construction was left attached. An access means was attached to die open end of die mbe as follows. A rod made of full density polytetrafluoroediylene was machined into a hollow mbular configuration about 0.94cm long comprising three main portions having an inner diameter of about 0.1cm. The first portion has an outer diameter of about 0.16cm, a length of about 0.30cm, and fits snugly inside the end of die tubular component of the apparams. The second portion has an outer diameter of about 0.2cm, a lengtii of about 0.20cm and functions as an abutment for the tube and die sealing means. The tiiird portion has an outer diameter of about 0.16cm, a length of about 0.30cm and serves to receive and retain a sealing means. A 2.0mm nominal inner diameter piece of fluorinated ediylene propylene (FEP) shrink-tube was placed over die first portion of die access means, trimmed to length, and heated widi a hot air gun to a temperature sufficient to shrink the FEP in place. The open end of the above-described tube was stretched slightly and gently placed over die FEP coated first portion of die access means up to die second portion of the access means. A second piece of FEP shrink-tube was placed over the mbe above the underlying FEP coated first portion of the access means. (See Figure 8, for example) The second piece of FEP was heated widi a hot air gun to a temperature sufficient to shrink the FEP over the mbe. Hot air was also used to partially melt botii die inner and die outer layers of FEP shrink-tube d ereby forming a strong bond between the stretched polytetrafluoroediylene tube and die access means. It is understood diat access means can be attached to botii ends of a mbular apparams by modifying die above-described procedure to accommodate a mbe having botii ends open. Example 2 A mbular apparams of die present invention having the pattern depicted in Figure 18 was made widi the same procedure described in Example 1. EΕarη Ie 3 Anodier mbular form of the present invention made of stretched polytetrafluoroethylene materials having a cell permeable zone beginning at the exterior surface of the tube and continuing across die tiiickness of die tube dirough to a cell exclusion zone witiiin die material adjacent to and continuous with the interior, or luminal, surface of the material is made as follows. The stretched polytetrafluoroediylene material is a laminate of two stretched polytetrafluoroethylene planar materials. The first stretched polytetrafluoroediylene material having a cell permeable zone with an average pore size of about 0.4 microns, as measured by porometry, and tiiickness of about 1 micron was made in accordance with the teachings of Bacino in U.S. Patent Application Serial No. 08/403,232 and corresponding PCT Application Serial No. PCT/US95/ , filed June 2, 1995, entitled "Porous PTFE Film And A Manufacturing Mediod Therefor" (hereinafter "Bacino material"), which is incorporated herein by reference. The second stretched polytetrafluoroethylene material having die cell exclusion zone witii an average pore size of about 5.0 microns, as measured by fibril length, and tiiickness of about 30 microns was made in accordance with the teachings of U.S. Patent Nos. 3,953,566 and 4, 187,390, botii issued to Gore (hereinafter "Gore material"), each of which is incorporated herein by reference. Once obtained, botii die Bacino and the Gore materials were individually spooled onto a polypropylene core, about 1.4cm in diameter, and dien slit lengtiiwise widi a razor blaze to a widtii of about 0.93cm. The Bacino material was then wrapped onto a highly polished 2.0mm diameter mandrel in a substantially helical fashion having an overlap of about 0.32cm from one layer of wrap to die next. The Gore material was wrapped onto die Bacino material in a helical fashion having an overlap of about 0.32cm from one layer of wrap to d e next. This construction was d en placed in an oven set to about 380'C for about seven (7) minutes to bond die wrapped layers of die Baciho and Gore materials to diem selves and to bond die Bacino material and die Gore material together to form a laminate. The laminate was men allowed to cool to room temperature before gently removing it from the mandrel. The laminate was removed from the mandrel by gently massaging it free in a twisting motion. Access means are attached to one or botii ends of die mbe as described in Example 1. Example 4 A mbular apparams of d e present invention having an essentially confluent cell exclusion zone formed wid a thermoplastic hydrogel material impregnated within the porous structure of a stretched polytetrafluoroedilyene material adjacent to and continuous widi die luminal surface of the tube was made as follows. A laminate of stretched polytetrafluoroediylene materials made in accordance widi die teachings of Gore, supra, having an average pore size at the luminal surface of about 5 microns, as measured by porometry, a fibril length of about 60 microns at die exterior surface of die material, and a tiiickness of about 600 microns was made into a tubular form. The hydrogel material HYPAN® Structural Hydrogel (10% HN-86 in dimeti yl sulfoxide (DMSO)) was impregnated in die stretched polytetrafluoroethylene material widi a spool shaped device that delivered die hydrogel material to die luminal surface of the tube as die device is moved dirough die luminal space of the tube. The outer diameter of the flange portions of the spool shaped device matched die inner diameter of me mbe to form a partial seal therewith. The center of the device was hollow and communicated widi holes in die indented sides of die spool shaped device. A delivery tube was attached to die hollow center of die device. Prior to impregnating the mbe with the hydrogel material, the tube is wetted with DMSO. Following wetting of die tube wim DMSO, die device was in place in die lumen of d e tube, hydrogel material was pumped dirough die delivery mbe and d e spool shaped device to the luminal surface of die tube at a rate of about 7.5 ml/hr. The hydrogel material was under pressure and entered die pores of die stretched polytetrafluoroethylene material adjacent to die luminal surface of d e tube to a deptii estimated to be between about 10% and 20% of me total tiiickness of die tube wall. The spool shaped device was moved along the length of die tube at a rate of about 26 cm/min while dispensing hydrogel onto die luminal surface of die tube and into the pores of die stretched polytetrafluoroediylene material. The impregnated hydrogel material was coagulated by injecting deionized water dirough d e luminal space of die mbe with a syringe. Example Eight containment apparatuses of the type described in Example 1, above, were tested in vivo for host response, neovascularization and tissue anchorage to the apparatuses. Test apparatuses were in the form of tubes approximately 2 mm in diameter and about 2.5 cm in length. Each apparatus had a single access means and contained a generally cylindrically shaped resilient core made of HYPAN® Structural Hydrogel HN-80 (Hymedix International, Inc., Dayton, NJ) to keep the mbe from collapsing once implanted and to simulate a dierapeutical device contained witiiin the apparams. The exterior surface of each HYPAN® Structural Hydrogel core was in direct contact widi die interior, or luminal, surface of each apparams along substantially the entire length of the core. Prior to implantation, the apparatuses were steam sterilized at 120'C for 20 minutes. The HYPAN® Structural Hydrogel core was made by mixing pellets of die hydrogel material, designated HN-80, at a concentration of about 20% in an aqueous solution of 55% sodium diiocyanate (NaSCN) to create a polymer solution having die consistency of honey. The polymer solution was extruded under water in a waterbath through a round die and taken up by the capstans also mounted under water. The diameter of die die was about 1.4mm. Once extruded, die hydrogel core was rinsed for about 24 hrs. in distilled water. On die day of implantation each apparams was dipped in 100% ethanol for approximately 2 seconds, followed by immersion in phosphate buffered saline pH 7.2 (GibcoBRL) for approximately 10 seconds to remove die ethanol. Due to die hydrophobic nature of die stretched polytetrafluoroediylene tiiis "wetting" procedure is necessary to assure filling of the interstices of e membrane widi liquid prior to implantation. The apparatuses remained submerged in fresh phosphate buffered saline until the core was inserted into die lumen of die apparatus dirough the open end of die mbe. The end was sealed widi a small band of silicone rubber tubing. The apparatuses were implanted subcutaneously in four Fischer rats. (Simonson Labs.) Each animal received two subcutaneous implants located on opposite sides of die dorsal midline of die body. To implant each apparatus, an incision was made in die skin of the rat and the subcutaneous tissue was blunt dissected approximately 4 cm just lateral to die dorsal midline. Implants were inserted into subcutaneous pockets and sutured at each end to die suocutaneous tissue using GORE-TEX® CV-5 Suture. (W.L. Gore & Associates, Inc., Flagstaff, AZ) The skin incision was closed with a simple interrupted suture. The in vivo responses to the implants were examined at two weeks and six weeks post implantation. Gross examination of the containment apparams in situ showed diat all apparatuses were anchored to surrounding host tissues at both two and six weeks. None of the apparatuses could be extracted widiout excision of the surrounding host tissues. This indicates diat each apparatus was fully anchored to die surrounding tissues as verified by the subsequent histology. Histological examination of each apparams showed that the implants were located in die subcutaneous space most commonly in die loose connective tissue between the cutaneous trunci and superficial skeletal muscles of die back of each rat. At two weeks, trichrome staining showed diat host connective tissue had invaded die cell permeable zone of each apparams to a position adjacent to, but not within, the cell exclusion zone of the apparatus. Many of the cells in the cell permeable zone after two weeks were of the leukocyte lineage. Host vasculature, predominately capillaries, had also invaded the cell permeable zone of d e apparams up to the cell exclusion zone. In each of the apparatuses, capillaries were within about 25 microns of d e lumen of die apparatus. After implantation for six weeks, histologic examination of each explanted apparatus showed fewer leukocytes remaining within die cell permeable zone of d e apparatus or in the tissue immediately surrounding the apparatus. This indicates d at a chronic inflammatory response was not caused by die implanted apparams. Host connective tissue and capillaries were still present within die cell permeable zone of the apparatus and could be seen located adjacent to die cell exclusion zone of die apparatus. The majority of host cells present after six weeks were of die fibroblast phenotype and were interspersed among connective tissue fibers diat were present within the cell permeable zone of die apparatuses. No cells or connective tissue were present in the cell exclusion zone of the apparatus or in the luminal space of d e apparatus. It is believed diat die thin, open microstructure of die cell permeable zone of the present invention permits the wound healing response of die implant recipient to create a vascular plexus close to the cell exclusion zone of d e apparams and within about 25 microns of die lumen of the apparams. Example 6 The preferred method of placing, retrieving, and replacing a therapeutical device in a mbular apparams of the present invention longer than a few centimeters having access means at both ends of die mbe is by flushing die dierapeutical device in and out of die apparams with a fluid stream. The metiiod is described using a mbular apparams of Example 1 having access means at bom ends of the tube. The apparatus is also illustrated in Figures 14 and 15C. Though not described in Example 1 or shown in Figures 14 and 15C, die apparams of this example has a HYPAN® Strucmral Hydrogel stent positioned within the entire length of the tube. In preparation for this experiment, the apparams was implanted subcutaneously in a greyhound dog and allowed to heal for two weeks. A resilient core of HYPAN® Strucmral Hydrogel having a generally cylindrical shape was used to simulate a therapeutical device in the method. Construction of die core is described in Example 5, above. Following a two week healing period, an incision was made in d e skin of the experimental animal above the location of me access means to expose die access means. Once the access means was exposed, die sealing means, caps, were removed from die access means. The HYPAN® Structural Hydrogel ste s were removed from the ends of die apparatus by forcing saline dirough the apparatus with a 20cc syringe causing die stent to squirt out the opposite end of the tube. The assemblies illustrated in Figure 15C include an apparatus of die present invention (1) having access means (2), holding means (3), and sealing means (4). Figure 15C also includes an illustration of two fluid stream means (5 and 6) and a connector (7), having a cavity widi a pin (8) on one side (hereinafter die "pin-side") and a cavity (9) on die other side of die connector (7) without a pin (hereinafter the "non-pin-side"), that was adapted to mate wid the access means (2) of d e apparams ( 1 ) to facilitate placement, retrieval, or replacement of die inert core in die apparams. To place the inert core in an apparatus of the type illustrated in Figure 15C, fluid stream means (5) was filled with an essentially isotonic saline solution. The end of die silicone tube of die fluid stream means attached to the non-pin-side (9) of connector (7) was disconnected from the connector. The inert hydrogel core was placed in the open end of the silicone mbe. The open end of the silicone mbe was reattached to connector (7) on the non-pin-side (9) of die connector. Fluid stream means (6) was attached to the pin-side (8) of connector (7). A fluid stream of saline was established with the syringe component of fluid stream means (5) through the silicone tubing entraining the inert hydrogel core in die fluid stream and carrying die core into die luminal space of the mbular apparams (1). The inert core is prevented from continuing through and out die opposite end of die apparams by retaining pin (8) in connector (7). Once the inert core was placed in die apparams, the fluid stream was discontinued. The connector (7) was removed from die access means of the apparatus (2) and replaced widi the sealing means (4). The sealed access means was mcked back under die skin and the incision closed. To remove the inert hydrogel core in the implanted apparatus, the sealed access means were surgically exposed, die sealing means (4) removed, and connector (7), widi fluid stream means (5 and 6) attached to die access means of the apparatus (2). A fluid stream was established dirough the apparams (1) with fluid stream means (6) around die inert hydrogel core, entraining die core in die fluid stream and moving it out of die apparatus into fluid stream means (5). To replace anodier inert hydrogel core in die implanted apparams, first die silicone mbe of fluid stream means (5) was disconnected from die non-pin-side (9) of connector (7) and die initial inert hydrogel core removed from fluid stream means (5). A second inert core was placed in the silicone tube of fluid stream means (5) and die open end of d e mbe reattached to die non-pin-side (9) of connector (7). The remaining steps are listed above and repeated accordingly.

Claims: CLAIMS What is claimed is: 1. An implantable containment apparams for a dierapeutical device comprising: a selectively permeable porous polymeric material in the form of a tube; wherein the mbe comprises an exterior surface, an interior surface that defines a luminal space of substantially uniform diameter, and an access means at one end of die tube through which a generally cylindrical dierapeutical device is insertable into die luminal space of the tube; wherein, once a dierapeutical device is inserted into the luminal space of die mbe, die dierapeutical device is retained witiiin the tube; wherein, biochemical and dierapeutic substances having a molecular weight up to about 5,000,000 MW diffuse across the thickness of the tube between the contents of die dierapeutical device contained dierein and tissues of a recipient; wherein the therapeutical device is removable from the tube dirough die access means of the tube; and wherein the tube is refillable with a therapeutical device dirough die access means of the tube. 2. The implantable containment apparatus of claim 1 wherein the therapeutical device retaing in die luminal space of die tube is preferably in direct contact with the interior surface of the tube along substantially the entire length of the therapeutical device. 3. The implantable containment apparatus of claim 1 wherein die tube has an access means at each end of die mbe. 4. The implantable containment apparatus of claim 1 wherein the selectively permeable porous polymeric material is selected from at least one member of a group consisting of stretched polytetrafluoroediylene, stretched polypropylene, stretched polyediylene, or porous polyvinylidene fluoride, either alone or in combination. 5. The implantable containment apparatus of claim 1 wherein die selectively permeable porous polymeric material comprises a laminate comprising a first layer serving as a cell exclusion zone comprised of a stretched polytetrafluoroethylene material having essentially no nodes, a thickness of about 1 micron, and an average pore size of about ranging from about 0.05 to about 0.4 micron, as measured by porometry, attached to a second layer serving as a cell permeable zone comprised of a stretched polytetrafluoroediylene material comprised of nodes and fibrils having a thickness ranging from about 10 microns to about 1000 microns and an average pore size greater tiian about 3 microns, as measured by fibril length. 6. The implantable containment apparams of claim 5 wherein the second layer of d e laminate is sufficiently porous to permit growth of vascular tissue from a recipient within the pores of the stretched polytetrafluoroediylene material up to, but not through, the cell exclusion zone. 7. The implantable containment apparams of claim 6 wherein the vascular tissue is capillary tissue. 8. The implantable containment apparams of claim 1 wherein the therapeutical device is a cell encapsulation device. 9. The implantable containment apparatus of claim 1 wherein the therapeutical device is a drug delivery device. 10. The implantable containment apparatus of claim 1 wherein the therapeutical device is a gene therapy device. 11. The implantable containment apparatus of claim 6 wherein die implantable containment apparatus, in conjunction with a cell encapsulation device, serves as an implantable medical device. 12. The implantable containment apparams of claim 11 wherein die implantable medical device is an artificial organ. 13. The implantable containment apparatus of claim 12 wherein die artificial organ is an artificial pancreas. 14. The implantable containment apparams of claim 3 wherein both access means of die tube are positioned and maintained sufficiently close to one another with a holding means diat the tube is implantable and accessible for filling and refilling widi a dierapeutical device at a single surgical site in a recipient. 15. The implantable containment apparatus of claim 1 having a plurality of generally cylindrically shaped tubes attached to a planar material in a radial array with the access means of each tube directed toward die center of die radial array. 16. The implantable containment apparatus of claim 3 wherein at least a portion of die tube is shaped into a plurality of convolutions and attached to a planar material to hold the tube in shape and maintain die access means close togedier. 17. The implantable containment apparatus of claim 1 having a plurality of generally cylindrically shaped tubes attached to a planar material oriented generally in parallel with respect to each other. 18. The implantable containment apparatus of claim 1 wherein the selectively permeable porous polymeric material comprises a stretched polytetrafluoroethylene material impregnated widi a layer of hydrogel material within the stretched polytetrafluoroethylene material adjacent to and continuous with the inner surface of the stretched polytetrafluoroethylene material ranging in tiiickness from about 1 micron to about 1000 microns, the hydrogel material serving as a cell exclusion zone, while remaining selectively permeable to biochemical and dierapeutical substances having a molecular weight up to about 5,000,000 MW. 19. The implantable containment apparams of claim 18 wherein the hydrogel is selected from at least one member of a group consisting of HYPAN® Structural Hydrogel, non-fibrogenic alginate, agarose, alginic acid, carrageenan, collagen, gelatin, polyvinyl alcohol, poly(2-hydroxyethyl mediacrylate, poly(N-vinyl- 2-pyτrolidone), or gellan gum, eidier alone or in combination. 20. The implantable containment apparatus of claim 18 wherein the stretched polytetrafluoroediylene material is sufficientiy porous to permit growth of vascular tissue from a recipient within the pores of die stretched polytetrafluoroethylene material up to, but not dirough, die hydrogel cell exclusion zone. 21. The implantable containment apparatus of claim 20 wherein die vascular tissue is capillary tissue. 22. The implantable containment apparams of claim 20 wherein the implantable containment apparams, in conjunction widi a cell encapsulation device, serves as an implantable medical device. 23. The implantable containment apparatus of claim 22 wherein the implantable medical device is an artificial organ. 24. The implantable containment apparatus of claim 23 wherein the artificial organ is an artificial pancreas. 25. The implantable containment apparatus of claim 18 wherein both access means of the tube are positioned and maintained sufficiently close to one another with a holding means so that the mbe is implantable and accessible for filling and refilling with a therapeutical device at a single site in a recipient. 26. The implantable containment apparams of claim 3 wherein a dierapeutical device is inserted and removed from the luminal space of the mbe with a fluid stream.

Inventors: BUTLER MARK D, DAVIDSON DANIEL F, MISH STANLEY L, MOORE JAMES W III, BUTLER, MARK, D., DAVIDSON, DANIEL, F., MISH, STANLEY, L., MOORE, JAMES, W., III
Applicants: GORE HYBRID TECHNOLOGIES INC, GORE HYBRID TECHNOLOGIES, INC.
Application year: 1996
Main classification: A61F2
IPC codes: A61F2, A61K9, A61L31, A61M37, A61N5